Australia's Telix Pharmaceuticals has announced the official opening of Telix Manufacturing Solutions (TMS) in Yokohama, Japan, the company's first cyclotron facility in the Asia Pacific region (APAC).
TMS Yokohama will enable Telix to provide greater access to radiopharmaceuticals for Japanese patients, initially through clinical supply of TLX250-CDx (a kidney cancer imaging candidate), with plans to supply other Telix investigational and future commercial products, including prostate and brain cancer precision diagnostics and therapies, subject to regulatory approval.
A commemorative lecture was held to mark the occasion, delivered by Professor Jun Hatazawa, Vice President of the Japan Isotope Association and Professor of the Next-Generation Cancer Therapy Research Division at Osaka University, entitled: 'Trends and Challenges for the Future of Nuclear Medicine'.
Raphael Ortiz, CEO International Business and Japan President at Telix, stated, "The opening of TMS Yokohama is a significant milestone for Telix as it enhances our capacity to meet growing demand for radiopharmaceuticals in Japan and Asia Pacific. As the world's second-largest nuclear medicine market, we have always considered Japan a key country in our clinical and commercial strategy."
TMS is a global network of 39 manufacturing and distribution facilities across five continents, equipping Telix to deliver commercial and clinical doses to patients globally. Capabilities span isotope production, translational research and radiochemistry, antibody engineering, bioconjugation, and finished radiopharmaceutical manufacturing and distribution.
